Tasimelteon: A selective and unique receptor binding profile
نویسندگان
چکیده
منابع مشابه
Tasimelteon: A selective and unique receptor binding profile
Hetlioz(®) (tasimelteon) is the first approved treatment in the United States for Non-24-Hour Sleep-Wake Disorder (Non-24). We present here data on the in vitro binding affinity of tasimelteon for both human melatonin receptors MT1 and MT2, as well as the extended screen of other receptors and enzymes. Results indicate that tasimelteon is a potent Dual Melatonin Receptor Agonist (DMRA) with 2.1...
متن کاملIdentification of a novel selective PPARγ ligand with a unique binding mode and improved therapeutic profile in vitro
Thiazolidinediones (TZD) function as potent anti-diabetic drugs through their direct action on the nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ), but their therapeutic benefits are compromised by severe side effects. To address this concern, here we developed a potent "hit" compound, VSP-51, which is a novel selective PPARγ-modulating ligand with improved therapeutic pro...
متن کاملSafety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies.
INTRODUCTION Tasimelteon, a novel circadian regulator, is the first product for the treatment of Non-24-hour Sleep-Wake Disorder (Non-24) approved by either the FDA or the European Medicines Agency (EMA). Tasimelteon is a potent and specific melatonin (MT1 and MT2) receptor agonist with 2 - 4 times greater affinity for the MT2 receptor. METHODS Safety was assessed in two controlled and two op...
متن کاملSelective disaccharide binding by a macrotetracyclic receptor.
A new carbohydrate receptor possesses a C3-symmetric polar cavity capable of encapsulating disaccharides; binding to beta-maltosyl is preferred, complementing previous systems which have favoured "all-equatorial" substrates.
متن کاملSOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.
OBJECTIVE The aim of the present study was to identify a small, metabolically stable somatotropin release inhibiting factor (SRIF) analog with a more universal binding profile similar to that of natural somatostatin, resulting in improved pharmacological properties and hence new therapeutic uses. DESIGN A rational drug design approach was followed by synthesizing alanine-substituted SRIF-14 a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuropharmacology
سال: 2015
ISSN: 0028-3908
DOI: 10.1016/j.neuropharm.2014.12.004